Clinical heterogeneity and treatment response in inclusion body myositis

Inclusion body myositis has been described as an inflammatory myopathy with distinctive clinical and pathologic features that is refractory to treatment. Ten cases of inclusion body myositis, as defined by histopathologic findings, were reviewed to determine whether the clinical characteristics are...

Full description

Saved in:
Bibliographic Details
Published in:Arthritis and rheumatism 1989-06, Vol.32 (6), p.734-740
Main Authors: Cohen, Miriam Richter, Sulaiman, A. R., Garancis, John C., Wortmann, Robert L.
Format: Article
Language:English
Subjects:
Adult
Aged
Azathioprine - therapeutic use
Biological and medical sciences
Female
Humans
Inclusion Bodies - pathology
Inclusion Bodies - ultrastructure
Male
Medical sciences
Microscopy, Electron
Middle Aged
Myositis - drug therapy
Myositis - pathology
Neurology
Prednisone - therapeutic use
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4751-b3a4d87925c4d44b0eaca659e428cccece667578194208c8ad279b0c261d2feb3
cites cdi_FETCH-LOGICAL-c4751-b3a4d87925c4d44b0eaca659e428cccece667578194208c8ad279b0c261d2feb3
container_end_page 740
container_issue 6
container_start_page 734
container_title Arthritis and rheumatism
container_volume 32
creator Cohen, Miriam Richter
Sulaiman, A. R.
Garancis, John C.
Wortmann, Robert L.
description Inclusion body myositis has been described as an inflammatory myopathy with distinctive clinical and pathologic features that is refractory to treatment. Ten cases of inclusion body myositis, as defined by histopathologic findings, were reviewed to determine whether the clinical characteristics are different in patients whose disease has been defined by light and electron microscopic studies compared with those whose disease has been defined by light microscopic studies alone. The clinical characteristics of both groups of patients were similar, and 2 patients have had excellent responses to treatment. Although inclusion body myositis represents a histologic subset of polymyositis, from a clinical perspective, it must be considered a nonspecific designation. Despite a generally poor prognosis, therapeutic intervention is still warranted.
doi_str_mv 10.1002/anr.1780320611
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79049407</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79049407</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4751-b3a4d87925c4d44b0eaca659e428cccece667578194208c8ad279b0c261d2feb3</originalsourceid><addsrcrecordid>eNqFkEtLxDAQgIMo67p69Sb0IN665tk0R1nUFRYEWc8hTacaadM1aZH-eytbVm_CwDDMNw8-hC4JXhKM6a3xYUlkjhnFGSFHaE4EVSkmjByjOcaYp0wocorOYvwYS8oEm6EZFZyTXMzRelU776ypk3foILRv4MF1Q2J8mXQBTNeA75IAcdf6CInzY9i6j671SdGWQ9IMbXSdi-fopDJ1hIspL9Drw_12tU43z49Pq7tNarkUJC2Y4WUuFRWWl5wXGIw1mVDAaW6tBQtZJoXMieIU5zY3JZWqwJZmpKQVFGyBbvZ7d6H97CF2unHRQl0bD20ftVSYK47lCC73oA1tjAEqvQuuMWHQBOsfdXpUp3_VjQNX0-a-aKA84JOrsX899U0chVXBeOviAZOMSyzpiKk99uVqGP45qu9etn9e-AY9wYfP</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79049407</pqid></control><display><type>article</type><title>Clinical heterogeneity and treatment response in inclusion body myositis</title><source>Wiley-Blackwell Journals (Backfile Content)</source><creator>Cohen, Miriam Richter ; Sulaiman, A. R. ; Garancis, John C. ; Wortmann, Robert L.</creator><creatorcontrib>Cohen, Miriam Richter ; Sulaiman, A. R. ; Garancis, John C. ; Wortmann, Robert L.</creatorcontrib><description>Inclusion body myositis has been described as an inflammatory myopathy with distinctive clinical and pathologic features that is refractory to treatment. Ten cases of inclusion body myositis, as defined by histopathologic findings, were reviewed to determine whether the clinical characteristics are different in patients whose disease has been defined by light and electron microscopic studies compared with those whose disease has been defined by light microscopic studies alone. The clinical characteristics of both groups of patients were similar, and 2 patients have had excellent responses to treatment. Although inclusion body myositis represents a histologic subset of polymyositis, from a clinical perspective, it must be considered a nonspecific designation. Despite a generally poor prognosis, therapeutic intervention is still warranted.</description><identifier>ISSN: 0004-3591</identifier><identifier>EISSN: 1529-0131</identifier><identifier>DOI: 10.1002/anr.1780320611</identifier><identifier>PMID: 2544185</identifier><identifier>CODEN: ARHEAW</identifier><language>eng</language><publisher>New York: John Wiley &amp; Sons, Inc</publisher><subject>Adult ; Aged ; Azathioprine - therapeutic use ; Biological and medical sciences ; Female ; Humans ; Inclusion Bodies - pathology ; Inclusion Bodies - ultrastructure ; Male ; Medical sciences ; Microscopy, Electron ; Middle Aged ; Myositis - drug therapy ; Myositis - pathology ; Neurology ; Prednisone - therapeutic use ; Time Factors</subject><ispartof>Arthritis and rheumatism, 1989-06, Vol.32 (6), p.734-740</ispartof><rights>Copyright © 1989 American College of Rheumatology</rights><rights>1989 INIST-CNRS</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4751-b3a4d87925c4d44b0eaca659e428cccece667578194208c8ad279b0c261d2feb3</citedby><cites>FETCH-LOGICAL-c4751-b3a4d87925c4d44b0eaca659e428cccece667578194208c8ad279b0c261d2feb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fanr.1780320611$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fanr.1780320611$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27924,27925,46049,46473</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=7347072$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2544185$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cohen, Miriam Richter</creatorcontrib><creatorcontrib>Sulaiman, A. R.</creatorcontrib><creatorcontrib>Garancis, John C.</creatorcontrib><creatorcontrib>Wortmann, Robert L.</creatorcontrib><title>Clinical heterogeneity and treatment response in inclusion body myositis</title><title>Arthritis and rheumatism</title><addtitle>Arthritis Rheum</addtitle><description>Inclusion body myositis has been described as an inflammatory myopathy with distinctive clinical and pathologic features that is refractory to treatment. Ten cases of inclusion body myositis, as defined by histopathologic findings, were reviewed to determine whether the clinical characteristics are different in patients whose disease has been defined by light and electron microscopic studies compared with those whose disease has been defined by light microscopic studies alone. The clinical characteristics of both groups of patients were similar, and 2 patients have had excellent responses to treatment. Although inclusion body myositis represents a histologic subset of polymyositis, from a clinical perspective, it must be considered a nonspecific designation. Despite a generally poor prognosis, therapeutic intervention is still warranted.</description><subject>Adult</subject><subject>Aged</subject><subject>Azathioprine - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Female</subject><subject>Humans</subject><subject>Inclusion Bodies - pathology</subject><subject>Inclusion Bodies - ultrastructure</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microscopy, Electron</subject><subject>Middle Aged</subject><subject>Myositis - drug therapy</subject><subject>Myositis - pathology</subject><subject>Neurology</subject><subject>Prednisone - therapeutic use</subject><subject>Time Factors</subject><issn>0004-3591</issn><issn>1529-0131</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><recordid>eNqFkEtLxDAQgIMo67p69Sb0IN665tk0R1nUFRYEWc8hTacaadM1aZH-eytbVm_CwDDMNw8-hC4JXhKM6a3xYUlkjhnFGSFHaE4EVSkmjByjOcaYp0wocorOYvwYS8oEm6EZFZyTXMzRelU776ypk3foILRv4MF1Q2J8mXQBTNeA75IAcdf6CInzY9i6j671SdGWQ9IMbXSdi-fopDJ1hIspL9Drw_12tU43z49Pq7tNarkUJC2Y4WUuFRWWl5wXGIw1mVDAaW6tBQtZJoXMieIU5zY3JZWqwJZmpKQVFGyBbvZ7d6H97CF2unHRQl0bD20ftVSYK47lCC73oA1tjAEqvQuuMWHQBOsfdXpUp3_VjQNX0-a-aKA84JOrsX899U0chVXBeOviAZOMSyzpiKk99uVqGP45qu9etn9e-AY9wYfP</recordid><startdate>198906</startdate><enddate>198906</enddate><creator>Cohen, Miriam Richter</creator><creator>Sulaiman, A. R.</creator><creator>Garancis, John C.</creator><creator>Wortmann, Robert L.</creator><general>John Wiley &amp; Sons, Inc</general><general>Wiley</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>198906</creationdate><title>Clinical heterogeneity and treatment response in inclusion body myositis</title><author>Cohen, Miriam Richter ; Sulaiman, A. R. ; Garancis, John C. ; Wortmann, Robert L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4751-b3a4d87925c4d44b0eaca659e428cccece667578194208c8ad279b0c261d2feb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Azathioprine - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Female</topic><topic>Humans</topic><topic>Inclusion Bodies - pathology</topic><topic>Inclusion Bodies - ultrastructure</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microscopy, Electron</topic><topic>Middle Aged</topic><topic>Myositis - drug therapy</topic><topic>Myositis - pathology</topic><topic>Neurology</topic><topic>Prednisone - therapeutic use</topic><topic>Time Factors</topic><toplevel>online_resources</toplevel><creatorcontrib>Cohen, Miriam Richter</creatorcontrib><creatorcontrib>Sulaiman, A. R.</creatorcontrib><creatorcontrib>Garancis, John C.</creatorcontrib><creatorcontrib>Wortmann, Robert L.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Arthritis and rheumatism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cohen, Miriam Richter</au><au>Sulaiman, A. R.</au><au>Garancis, John C.</au><au>Wortmann, Robert L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical heterogeneity and treatment response in inclusion body myositis</atitle><jtitle>Arthritis and rheumatism</jtitle><addtitle>Arthritis Rheum</addtitle><date>1989-06</date><risdate>1989</risdate><volume>32</volume><issue>6</issue><spage>734</spage><epage>740</epage><pages>734-740</pages><issn>0004-3591</issn><eissn>1529-0131</eissn><coden>ARHEAW</coden><abstract>Inclusion body myositis has been described as an inflammatory myopathy with distinctive clinical and pathologic features that is refractory to treatment. Ten cases of inclusion body myositis, as defined by histopathologic findings, were reviewed to determine whether the clinical characteristics are different in patients whose disease has been defined by light and electron microscopic studies compared with those whose disease has been defined by light microscopic studies alone. The clinical characteristics of both groups of patients were similar, and 2 patients have had excellent responses to treatment. Although inclusion body myositis represents a histologic subset of polymyositis, from a clinical perspective, it must be considered a nonspecific designation. Despite a generally poor prognosis, therapeutic intervention is still warranted.</abstract><cop>New York</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>2544185</pmid><doi>10.1002/anr.1780320611</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0004-3591
ispartof Arthritis and rheumatism, 1989-06, Vol.32 (6), p.734-740
issn 0004-3591
1529-0131
language eng
recordid cdi_proquest_miscellaneous_79049407
source Wiley-Blackwell Journals (Backfile Content)
subjects Adult
Aged
Azathioprine - therapeutic use
Biological and medical sciences
Female
Humans
Inclusion Bodies - pathology
Inclusion Bodies - ultrastructure
Male
Medical sciences
Microscopy, Electron
Middle Aged
Myositis - drug therapy
Myositis - pathology
Neurology
Prednisone - therapeutic use
Time Factors
title Clinical heterogeneity and treatment response in inclusion body myositis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T07%3A09%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20heterogeneity%20and%20treatment%20response%20in%20inclusion%20body%20myositis&rft.jtitle=Arthritis%20and%20rheumatism&rft.au=Cohen,%20Miriam%20Richter&rft.date=1989-06&rft.volume=32&rft.issue=6&rft.spage=734&rft.epage=740&rft.pages=734-740&rft.issn=0004-3591&rft.eissn=1529-0131&rft.coden=ARHEAW&rft_id=info:doi/10.1002/anr.1780320611&rft_dat=%3Cproquest_cross%3E79049407%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4751-b3a4d87925c4d44b0eaca659e428cccece667578194208c8ad279b0c261d2feb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=79049407&rft_id=info:pmid/2544185&rfr_iscdi=true